Eton Pharmaceuticals (NASDAQ:ETON) Receives New Coverage from Analysts at Craig Hallum

Craig Hallum began coverage on shares of Eton Pharmaceuticals (NASDAQ:ETON) in a research note issued to investors on Monday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $8.00 price target on the stock. Craig Hallum’s price objective points to a potential upside of 115.05% from the company’s current price.

Eton Pharmaceuticals Price Performance

Shares of ETON stock opened at $3.72 on Monday. The firm has a market cap of $95.57 million, a P/E ratio of -124.00 and a beta of 1.19. The firm has a fifty day moving average of $3.75 and a two-hundred day moving average of $4.07. Eton Pharmaceuticals has a 1-year low of $2.42 and a 1-year high of $5.81.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.05). The firm had revenue of $7.31 million for the quarter, compared to analyst estimates of $7.70 million. Eton Pharmaceuticals had a negative net margin of 2.96% and a negative return on equity of 6.21%.

Institutional Trading of Eton Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of ETON. Westside Investment Management Inc. grew its position in shares of Eton Pharmaceuticals by 6.6% during the 4th quarter. Westside Investment Management Inc. now owns 563,110 shares of the company’s stock valued at $2,466,000 after buying an additional 34,800 shares during the last quarter. EAM Investors LLC acquired a new stake in shares of Eton Pharmaceuticals during the 3rd quarter worth approximately $1,070,000. Acuitas Investments LLC raised its position in shares of Eton Pharmaceuticals by 124.7% during the 4th quarter. Acuitas Investments LLC now owns 492,054 shares of the company’s stock worth $2,155,000 after purchasing an additional 273,054 shares during the period. Bailard Inc. bought a new stake in shares of Eton Pharmaceuticals in the 4th quarter worth approximately $99,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Eton Pharmaceuticals during the 3rd quarter valued at approximately $160,000. 27.86% of the stock is owned by institutional investors and hedge funds.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.